Acrolein-mediated alpha-synuclein pathology involvement in the early post-injury pathogenesis of mild blast-induced Parkinsonian neurodegeneration

Mol Cell Neurosci. 2019 Jul:98:140-154. doi: 10.1016/j.mcn.2019.06.004. Epub 2019 Jun 12.

Abstract

Survivors of blast-induced traumatic brain injury (bTBI) have increased susceptibility to Parkinson's disease (PD), characterized by α-synuclein aggregation and the progressive degeneration of nigrostriatal dopaminergic neurons. Using an established bTBI rat model, we evaluated the changes of α-synuclein and tyrosine hydroxylase (TH), known hallmarks of PD, and acrolein, a reactive aldehyde and marker of oxidative stress, with the aim of revealing key pathways leading to PD post-bTBI. Indicated in both animal models of PD and TBI, acrolein is likely a point of pathogenic convergence. Here we show that after a single mild bTBI, acrolein is elevated up to a week, systemically in urine, and in whole brain tissue, specifically the substantia nigra and striatum. Acrolein elevation is accompanied by heightened α-synuclein oligomerization, dopaminergic dysregulation, and acrolein/α-synuclein interaction in the same brain regions. We further show that acrolein can directly modify and oligomerize α-synuclein in vitro. Taken together, our data suggests acrolein likely plays an important role in inducing PD pathology following bTBI by encouraging α-synuclein aggregation. These results are expected to advance our understanding of the long-term post-bTBI pathological changes leading to the development of PD, and suggest intervention targets to curtail such pathology.

Keywords: Acrolein; Neurodegeneration; Neuroinflammation; Neurotrauma; Oxidative stress; Parkinson's disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acrolein / metabolism*
  • Acrolein / pharmacology
  • Animals
  • Brain Injuries, Traumatic / complications*
  • Corpus Striatum / metabolism
  • Male
  • Parkinson Disease, Secondary / etiology
  • Parkinson Disease, Secondary / metabolism*
  • Protein Multimerization / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Substantia Nigra / metabolism
  • Tyrosine 3-Monooxygenase / metabolism
  • alpha-Synuclein / metabolism*

Substances

  • alpha-Synuclein
  • Acrolein
  • Tyrosine 3-Monooxygenase